

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in targeted therapy for Ewing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2077/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2077" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in targeted therapy for Ewing sarcoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in targeted therapy for Ewing sarcoma.">
            <meta name="og:description" content="Read the latest article version by Kathleen I. Pishas, Stephen L. Lessnick, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9285">
            <meta name="article-id" content="8631">
            <meta name="dc.title" content="Recent advances in targeted therapy for Ewing sarcoma">
            <meta name="dc.description" content="Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to improve overall survival for this subset of patients highlights the urgent need for rapid translation of novel therapeutic strategies. As Ewing sarcoma is associated with a paucity of mutations in readily targetable signal transduction pathways, targeting the key genetic aberration and master regulator of Ewing sarcoma, the EWS/ETS fusion, remains an important goal.">
            <meta name="dc.subject" content="Ewing sarcoma, sarcoma, ganitumab, EWS/FLI, ">
            <meta name="dc.creator" content="Pishas, Kathleen I.">
            <meta name="dc.creator" content="Lessnick, Stephen L.">
            <meta name="dc.date" content="2016/08/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.8631.1">
            <meta name="dc.source" content="F1000Research 2016 5:2077">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Ewing sarcoma ">
            <meta name="prism.keyword" content=" sarcoma ">
            <meta name="prism.keyword" content=" ganitumab ">
            <meta name="prism.keyword" content=" EWS/FLI ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/08/25">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2077">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.8631.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2077">
            <meta name="citation_title" content="Recent advances in targeted therapy for Ewing sarcoma">
            <meta name="citation_abstract" content="Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to improve overall survival for this subset of patients highlights the urgent need for rapid translation of novel therapeutic strategies. As Ewing sarcoma is associated with a paucity of mutations in readily targetable signal transduction pathways, targeting the key genetic aberration and master regulator of Ewing sarcoma, the EWS/ETS fusion, remains an important goal.">
            <meta name="citation_description" content="Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to improve overall survival for this subset of patients highlights the urgent need for rapid translation of novel therapeutic strategies. As Ewing sarcoma is associated with a paucity of mutations in readily targetable signal transduction pathways, targeting the key genetic aberration and master regulator of Ewing sarcoma, the EWS/ETS fusion, remains an important goal.">
            <meta name="citation_keywords" content="Ewing sarcoma, sarcoma, ganitumab, EWS/FLI, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kathleen I. Pishas">
            <meta name="citation_author_institution" content="Cancer Therapeutics Laboratory, Center for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia">
            <meta name="citation_author_institution" content="Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA">
            <meta name="citation_author" content="Stephen L. Lessnick">
            <meta name="citation_author_institution" content="Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA">
            <meta name="citation_author_institution" content="Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Ohio State University, Columbus, OH, USA">
            <meta name="citation_publication_date" content="2016/08/25">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2077">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.8631.1">
            <meta name="citation_firstpage" content="2077">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2077/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2077.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9285 /> <input type=hidden id=articleId name=articleId value=8631 /> <input type=hidden id=xmlUrl value="/articles/5-2077/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2077-v1.xml"> <input type=hidden id=article_uuid value=afc4d3b2-6c63-4924-9114-0aad794821f5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in targeted therapy for Ewing sarcoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.8631.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.8631.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2077"
  },
  "headline": "Recent advances in targeted therapy for Ewing sarcoma",
  "datePublished": "2016-08-25T15:26:18",
  "dateModified": "2016-08-25T15:26:18",
  "author": [
    {
      "@type": "Person",
      "name": "Kathleen I. Pishas"
    },    {
      "@type": "Person",
      "name": "Stephen L. Lessnick"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to improve overall survival for this subset of patients highlights the urgent need for rapid translation of novel therapeutic strategies. As Ewing sarcoma is associated with a paucity of mutations in readily targetable signal transduction pathways, targeting the key genetic aberration and master regulator of Ewing sarcoma, the EWS/ETS fusion, remains an important goal."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2077.html",
            "name": "Recent advances in targeted therapy for Ewing sarcoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in targeted therapy for Ewing sarcoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9285 data-id=8631 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8631.1" data-recommended="" data-doi="10.12688/f1000research.8631.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2077/v1/pdf?article_uuid=afc4d3b2-6c63-4924-9114-0aad794821f5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-8631-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-8631-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-8631-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Pishas KI and Lessnick SL. Recent advances in targeted therapy for Ewing sarcoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2077 (<a class=new-orange href="https://doi.org/10.12688/f1000research.8631.1" target=_blank>https://doi.org/10.12688/f1000research.8631.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-8631-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=8631 id=track-article-signin-8631 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8631?target=/articles/5-2077.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9285 /> <input name=articleId type=hidden value=8631 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in targeted therapy for Ewing sarcoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Kathleen I. Pishas<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:stephen.lessnick@nationwidechildrens.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Stephen L. Lessnick</span></a><sup>2,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Kathleen I. Pishas<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:stephen.lessnick@nationwidechildrens.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Stephen L. Lessnick</span></a><sup>2,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Aug 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.8631.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Cancer Therapeutics Laboratory, Center for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia<br/> <sup>2</sup> Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA<br/> <sup>3</sup> Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Ohio State University, Columbus, OH, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16718-15889></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16717-15890></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to their disease. The persistent failure to improve overall survival for this subset of patients highlights the urgent need for rapid translation of novel therapeutic strategies. As Ewing sarcoma is associated with a paucity of mutations in readily targetable signal transduction pathways, targeting the key genetic aberration and master regulator of Ewing sarcoma, the EWS/ETS fusion, remains an important goal. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Ewing sarcoma, sarcoma, ganitumab, EWS/FLI, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Stephen L. Lessnick (<a href="mailto:stephen.lessnick@nationwidechildrens.org">stephen.lessnick@nationwidechildrens.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Stephen L. Lessnick </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> KIP declares that she has no competing interests. SLL is the Acting Chief Medical Officer for Salarius Pharmaceuticals, LLC, (Salt Lake City, UT). </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> SLL was supported by National Institutes of Health/National Cancer Institute grants R01 CA140394 and R01 CA183776, the Pediatric Cancer Foundation Sunshine Project, and the Alan B. Slifka Foundation. KIP acknowledges financial support from the University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship and the National Health and Medical Research Council CJ Martin Overseas Biomedical Fellowship. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Pishas KI and Lessnick SL. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Pishas KI and Lessnick SL. Recent advances in targeted therapy for Ewing sarcoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2077 (<a href="https://doi.org/10.12688/f1000research.8631.1" target=_blank>https://doi.org/10.12688/f1000research.8631.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Aug 2016, <b>5</b>(F1000 Faculty Rev):2077 (<a href="https://doi.org/10.12688/f1000research.8631.1" target=_blank>https://doi.org/10.12688/f1000research.8631.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Aug 2016, <b>5</b>(F1000 Faculty Rev):2077 (<a href="https://doi.org/10.12688/f1000research.8631.1" target=_blank>https://doi.org/10.12688/f1000research.8631.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e187>Introduction</h2><p class="" id=d2834e190>Despite our burgeoning knowledge of the molecular and pathognomonic foundation of Ewing sarcoma oncogenesis, improvement in the survival of patients with primary metastatic or relapsed disease remains obstinately poor, with long-term survival rates of less than 30%<sup><a href="#ref-1">1</a></sup>. Ewing sarcoma is an aggressive, rare bone malignancy that primarily afflicts young adolescents in the second decade of life. Approximately 20–25% of patients present with clinically detectable metastases at diagnosis<sup><a href="#ref-2">2</a></sup>, and those lacking overt disease likely harbor micro-metastases as evident by the high rate of relapse at distant sites following surgical resection. Although the advent of multi-agent adjuvant chemotherapy has achieved remarkable progress in the treatment of localized disease (65–75% 5-year survival rate), no standard therapy exists for second-line treatment of relapsed and refractory Ewing sarcoma, despite extensive protocol-driven clinical research evaluating dose intensification and schedule optimization.</p><p class="" id=d2834e201>Ewing sarcoma is an orphan cancer; its parental lineage is unknown and is frequently disputed still to this day<sup><a href="#ref-3">3</a></sup>. The oncogenic phenotype is primarily driven by one underlying prototypical chromosomal translocation, fusion of the <i>EWS</i> gene on chromosome 22q24 with one of five E-twenty-six (ETS) transcription factor gene family members (<i>FLI</i><sup><a href="#ref-4">4</a></sup>, <i>ERG</i><sup><a href="#ref-5">5</a></sup>, <i>ETV1</i><sup><a href="#ref-6">6</a></sup>, <i>E1AF</i><sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>, and <i>FEV</i><sup><a href="#ref-9">9</a></sup>). Of the EWS/ETS translocations, 85% of Ewing’s tumors harbor the EWS/FLI reciprocal translocation t(11;22)(q24;q12), which links the strong transcriptional activation domain of the EWS protein to the ETS DNA-binding domain of the FLI protein<sup><a href="#ref-10">10</a></sup>. The resulting chimeric EWS/FLI fusion functions as a constitutively active transcription factor which regulates a myriad of genes required for the oncogenic behavior of Ewing sarcoma. EWS/FLI binds DNA at either ETS-like consensus purine-rich sites containing a core GGAA motif or repetitive GGAA-microsatellite elements embedded within promoter/enhancer regions of numerous target genes. Indeed, 40–50% of genomic EWS/FLI-binding sites are associated with GGAA-microsatellites<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d2834e254>As Ewing sarcoma possesses one of the lowest mutation rates among all cancers (0.15 mutations per megabase)<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>, the nefarious activity of EWS/FLI has long been considered the ideal therapeutic target. Although the t(11;22)(q24;q12) translocation was first described 33 years ago<sup><a href="#ref-14">14</a></sup> and numerous studies have validated that the tumorigenic phenotype of Ewing sarcoma is dependent on this master regulator, EWS/FLI-targeted therapies are only now beginning to be clinically evaluated. Constraining the Achilles’ heel of Ewing sarcoma has proven to be extremely problematic. Fusion proteins are notoriously challenging targets because of their disordered protein nature and lack of intrinsic enzymatic activity.</p><p class="" id=d2834e268>The primary focus of this review is to highlight the recent advances and new therapeutic developments for this aggressive neoplasm, and the particular focus is on four classes of experimental agents: (i) targeted agents that disrupt the binding of EWS/FLI to key functional protein partners, (ii) agents that reverse the transcriptional signature of EWS/FLI, (iii) inhibitors of LSD1 (lysine-specific demethylase 1), and (iv) inhibitors of PARP-1 (poly ADP ribose polymerase-1).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e274>Targeting EWS/FLI: the untouchable Achilles’ heel of Ewing sarcoma</h2><p class="" id=d2834e277>The EWS/FLI<i></i> translocation primarily serves as the most reliable diagnostic marker and, in the majority of cases, sole genetic aberration that drives Ewing sarcoma oncogenesis. Despite this prime candidate vulnerability, clinical translation of therapeutic strategies directed toward eliminating or inactivating EWS/FLI has been largely unsuccessful. Since the cloning of the EWS/FLI translocation in 1992<sup><a href="#ref-4">4</a></sup>, several studies have demonstrated the critical nature of EWS/FLI to maintain the oncogenic growth of Ewing sarcoma cells. Reduction of EWS/FLI fusion levels through anti-sense/small interfering RNA (siRNA) or oligodeoxynucleotides significantly impairs the proliferative, invasive, and tumorigenic phenotype of Ewing sarcoma both <i>in vitro</i> and <i>in vivo</i><sup><a href="#ref-15">15</a>–<a href="#ref-19">19</a></sup>.<i></i> However, owing to poor pharmacokinetic properties, these approaches are not currently clinically feasible<i>.</i> An inherent disadvantage of oncogenic transcription factors such as EWS/FLI in terms of “druggability” is their lack of intrinsic enzymatic activity. This, coupled with the disordered nature of the EWS/FLI protein (inability to form rigid three-dimensional structures under physiological conditions), which is due to low overall hydrophobicity, preludes standard structure-based small-molecule inhibitor design through crystallographic structural assessment<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. As EWS/FLI requires disorder to achieve maximal transactivation of transcription and to facilitate the protein-protein complexes that lead to oncogenesis, directed small-molecule disruption of EWS/FLI from key functional protein partners or transcriptional complexes (or both) has gained considerable attention over the past decade.</p><p class="" id=d2834e311>To define proteins that directly interact and functionally modulate EWS/FLI, Toretsky <i>et al.</i> undertook phage library screening to identify peptides that could bind recombinant EWS/FLI<sup><a href="#ref-22">22</a></sup>. From the 28 peptides identified, EWS/FLI was shown to bind to the distal portion of the helicase domain of RNA helicase A (RHA) (K<sub>D</sub> of 9.48 µM). Given that RHA enhanced EWS/FLI-modulated transcription, subsequent surface plasmon resonance screening of 3,000 compounds capable of binding monomeric EWS/FLI identified YK-4-279, a small molecule that could effectively dissociate EWS/FLI from RHA (<a href="#f1">Figure 1</a>). Owing to the chiral center of YK-4-279, comparisons of (S) and (R)-YK-4-279 enantiomer forms revealed that only racemic and the (S)-YK-4-279 enantiomer are able to block the interaction of EWS/FLI with RHA resulting in cell cytotoxicity and reduced EWS/FLI-driven transcriptional activation<sup><a href="#ref-23">23</a></sup>. Although Ewing sarcoma cell lines were highly sensitive to (S)-YK-4-279 compared with racemic, the short plasma half-life (0.585 and 0.583 hours, respectively) and low oral bioavailability of YK-4-279 could pose significant clinical challenges. Rates of absolute bioavailability of (S)-YK-4-279 following oral gavage in rats and intraperitoneal injection in mice were only 2–6% and 26%, respectively<sup><a href="#ref-24">24</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9285/3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure1.gif"><img alt="3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9285/3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure1.gif"></a><div class=caption><h3>Figure 1. Chemical structures of Ewing sarcoma investigational agents.</h3></div></div><p class="" id=d2834e350>Although YK-4-279 was first thought to directly impede EWS/FLI-driven transcriptional activation, Selvanathan <i>et al.</i> recently demonstrated that the precise mechanism of action of YK-4-279 is through disruption of EWS/FLI protein interactions within the spliceosome leading to alternative splicing events that mirror EWS/FLI reduction<sup><a href="#ref-25">25</a></sup>. Indeed, initial Ewing sarcoma cell line viability assays demonstrated YK-4-279 anti-proliferative IC<sub>50</sub> (half maximal inhibitory concentration) values of 0.5–2 µM, yet dissociation of EWS/FLI from RHA was achieved only following 10 μM YK-4-279 treatment<sup><a href="#ref-22">22</a></sup>. In verification of this new mechanism of action, YK-4-279 treatment did not mimic the transcriptional effects of EWS/FLI reduction, as only <i>VEGFA</i> and <i>TGFβR2</i> transcripts were altered in a fashion consistent with EWS/FLI reduction<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d2834e379>A near-universal problem in the era of targeted therapy is the emergence of primary or secondary drug resistance that permits tumor progression. Regardless of the route of YK-4-279 administration, sustained complete responses were not documented across a complete cohort of treated animals<sup><a href="#ref-22">22</a>,<a href="#ref-24">24</a>,<a href="#ref-26">26</a></sup>. As such, Lamhamedi-Cherradi <i>et al.</i> recently investigated both <i>de novo</i> and acquired mechanism(s) in which Ewing sarcoma cells evade YK-4-279-mediated apoptosis<sup><a href="#ref-26">26</a></sup>. YK-4-279 drug-resistant clones demonstrated enhanced proliferative rate over their parental cell lines and overexpressed c-Kit, cyclin D1, pStat3 (Y705) protein, and PKC isoforms β and δ. In contrast, pro-apoptotic proteins (such as Bim, Bax, Bid, and Bak) were significantly downregulated<sup><a href="#ref-26">26</a></sup>. In addition, YK-4-279 drug-resistant cells displayed significant cross-resistance to both the PKC inhibitor enzastaurin and the US Food and Drug Administration-approved c-Kit inhibitor imatinib.</p><p class="" id=d2834e406>YK-4-279 is the first EWS/FLI precision-guided drug candidate to show preclinical activity in Ewing sarcoma, and a phase 1 dose escalation study of intravenous TK216 (clinical derivative of YK-4-279) in patients with relapsed or refractory Ewing sarcoma (NCT02657005) is currently active for patient recruitment (<a href="#T1">Table 1</a>). The dosing schedule, administration route, and decision to use either racemic or (S)-YK-4-279 will have profound implications for clinical efficacy and resistance. It is with great anticipation that YK-4-279 can change the perceived dogma that transcription factors such as EWS/FLI are ubiquitously “undruggable”.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Current Ewing sarcoma clinical trials.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2834e423 class=n-a></a><thead><a name=d2834e425 class=n-a></a><tr><a name=d2834e427 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e429 class=n-a></a>Agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e432 class=n-a></a>Trial identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e435 class=n-a></a>Sponsor</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e438 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e441 class=n-a></a>Age, years</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e445 class=n-a></a>Status</th></tr></thead><tbody><a name=d2834e450 class=n-a></a><tr><a name=d2834e452 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e454 class=n-a></a>PARP inhibition</td><td align=left colspan=1 rowspan=1><a name=d2834e457 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e459 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e461 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e463 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e466 class=n-a></a></td></tr><tr><a name=d2834e469 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e471 class=n-a></a>Talazoparib and temozolomide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e474 class=n-a></a>NCT02116777</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e477 class=n-a></a>NCI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e480 class=n-a></a>I/II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e483 class=n-a></a>1–30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e487 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e491 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e493 class=n-a></a>Niraparib and temozolomide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e496 class=n-a></a>NCT02044120</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e499 class=n-a></a>SARC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e502 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e505 class=n-a></a>&gt;13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e509 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e513 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e515 class=n-a></a>Talazoparib (BMN-673)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e518 class=n-a></a>NCT01286987</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e521 class=n-a></a>Medivation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e524 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e527 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e531 class=n-a></a>Active</td></tr><tr><a name=d2834e535 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e537 class=n-a></a>Olaparib and temozolomide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e540 class=n-a></a>NCT01858168</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e543 class=n-a></a>MGH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e546 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e549 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e553 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e558 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e560 class=n-a></a>Olaparib and trabectedin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e563 class=n-a></a>NCT02398058</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e566 class=n-a></a>Italian Sarcoma Group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e569 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e572 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e576 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e580 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e582 class=n-a></a>Kinase inhibition</td><td align=left colspan=1 rowspan=1><a name=d2834e585 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e587 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e589 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e591 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e594 class=n-a></a></td></tr><tr><a name=d2834e597 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e599 class=n-a></a>Pazopanib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e602 class=n-a></a>NCT01956669</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e605 class=n-a></a>Novartis/COG</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e608 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e611 class=n-a></a>1–18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e615 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e619 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e621 class=n-a></a>Cabozantinib-s-malate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e624 class=n-a></a>NCT02243605</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e627 class=n-a></a>NCI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e630 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e633 class=n-a></a>&gt;12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e637 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e641 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e643 class=n-a></a>Regorafenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e646 class=n-a></a>NCT02389244</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e649 class=n-a></a>UniCancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e652 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e655 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e659 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e665 class=n-a></a>Regorafenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e668 class=n-a></a>NCT02048371</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e671 class=n-a></a>SARC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e674 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e677 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e681 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e686 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e688 class=n-a></a>EWS/FLI inhibition</td><td align=left colspan=1 rowspan=1><a name=d2834e691 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e693 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e695 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e697 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e700 class=n-a></a></td></tr><tr><a name=d2834e703 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e705 class=n-a></a>TK216</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e708 class=n-a></a>NCT02657005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e711 class=n-a></a>Tokalas</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e714 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e717 class=n-a></a>&gt;12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e721 class=n-a></a>Active</td></tr><tr><a name=d2834e725 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e727 class=n-a></a>Miscellaneous</td><td align=left colspan=1 rowspan=1><a name=d2834e730 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e732 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e734 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e736 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d2834e739 class=n-a></a></td></tr><tr><a name=d2834e742 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e744 class=n-a></a>Erlotinib in combination with temozolomide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e747 class=n-a></a>NCT02689336</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e750 class=n-a></a>Washington University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e753 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e756 class=n-a></a>1–21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e760 class=n-a></a>Not Open</td></tr><tr><a name=d2834e764 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e766 class=n-a></a>Abemaciclib (LY2835219) (CDK4/6 inhibition)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e769 class=n-a></a>NCT02644460</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e772 class=n-a></a>Cynthia Wetmore</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e775 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e778 class=n-a></a>2–21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e782 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e786 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e788 class=n-a></a>hu14.18K322A (anti-GD2 antibody)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e791 class=n-a></a>NCT00743496</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e794 class=n-a></a>St. Jude Hospital</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e797 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e800 class=n-a></a>&lt;21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e804 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e809 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e811 class=n-a></a>Nivolumab with or without ipilimumab (IgG4<br class=br>anti-PD-1 antibody)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e816 class=n-a></a>NCT02304458</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e819 class=n-a></a>NCI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e822 class=n-a></a>I/II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e825 class=n-a></a>1–30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e829 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e833 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e835 class=n-a></a>Lurbinectedin (PM01183)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e838 class=n-a></a>NCT02454972</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e841 class=n-a></a>PharmaMar</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e844 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e847 class=n-a></a>&gt;18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e851 class=n-a></a>Recruiting</td></tr><tr><a name=d2834e855 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e857 class=n-a></a>Linsitinib (anti-IGF-1R)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e860 class=n-a></a>NCT02546544</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e863 class=n-a></a>University of Oxford</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e866 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e869 class=n-a></a>18–70 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e873 class=n-a></a>Recruiting</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN1 class=n-a></a><p id=d2834e882> COG, Children’s Oncology Group; MGH, Massachusetts General Hospital; NCI, National Cancer Institute; PARP, poly ADP ribose polymerase; SARC, Sarcoma Alliance for Research through Collaboration.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e890>Reversing <i>EWS/FLI</i> gene signatures</h2><p class="" id=d2834e896>The oncogenic phenotype of Ewing sarcoma is driven by the activating and repressive transcriptional functions of EWS/FLI<sup><a href="#ref-27">27</a></sup>. As such, therapeutic agents that can potentially reverse EWS/FLI-driven signatures and subsequently block the malignant proclivity of Ewing sarcoma have been an area of active interest by several groups. Trabectedin (ET-743, <i>Yondelis</i>), a synthetic alkaloid originally isolated from the marine ascidian <i>Ecteinascidia turbinata</i>, was recently shown to reverse the myxoid liposarcoma transcriptional program through DNA-binding inhibition of the oncogenic transcription factor FUS-CHOP<sup><a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. It is proposed that trabectedin (<a href="#f1">Figure 1</a>) binds and alkylates DNA at the N2 position of guanine in the minor groove<sup><a href="#ref-31">31</a></sup>. Once bound, this reversible covalent adduct bends DNA toward the major groove, interferes directly with activated transcription, inhibits transcription-coupled nucleotide excision repair, promotes degradation of RNA polymerase II, and generates DNA double-strand breaks, leading to S and G<sub>2</sub> cell cycle arrest<sup><a href="#ref-32">32</a></sup>. Grohar <i>et al.</i> demonstrated that Ewing sarcoma cell lines, in addition to myxoid liposarcomas, are particularly sensitive to the apoptotic effects of trabectedin compared with other fusion transcription factor-driven tumors, including embryonal/alveolar rhabdomyosarcoma and synovial sarcoma<sup><a href="#ref-33">33</a></sup>. Although protein levels of EWS/FLI remained unaffected following treatment, trabectedin reversed the EWS/FLI-induced gene expression signature, resulting in blockade of promoter activity and suppressed expression of critical EWS/FLI downstream targets such as NR0B1. Interestingly, of the four Ewing sarcoma cell lines tested, 5838 cells harboring the EWS/ERG translocation were the least sensitive. The authors suggest that this differential sensitivity may be attributed to the ERG transcription factor-binding domain which does not have a preferred trabectedin-binding site (CGG) overlapping its binding domain.</p><p class="" id=d2834e938>To develop trabectedin-based combination therapy with improved EWS/FLI suppression, Grohar <i>et al.</i> sought to identify genes driven by EWS/FLI that were suppressed following trabectedin treatment<sup><a href="#ref-34">34</a></sup>. A significant reduction in mRNA expression of the DNA damage response (DDR) REC Q helicase Werner syndrome protein (WRN) was observed following trabectedin treatment. Several studies have demonstrated that camptothecins can also directly suppress critical EWS/FLI downstream targets, including ID2 and NR0B1<sup><a href="#ref-35">35</a></sup>. Since cells deficient in WRN are hypersensitive to the cytotoxic effects of camptothecins<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>, Grohar <i>et al.</i> investigated whether trabectedin could selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38 (active metabolite of irinotecan)<sup><a href="#ref-34">34</a></sup>. Compared with single-agent treatment <i>in vivo</i>, combinatorial treatment synergistically augmented the suppression of EWS/FLI targets, leading to enhanced formation of γH2AX foci (DNA double-strand breaks) and accumulation of cells in S phase. Furthermore, marked complete regression of xenograft tumors that persisted following withdrawal of treatment was observed with combination therapy that was more pronounced than treatment with either agent alone. In addition to camptothecins, insulin-like growth factor 1 receptor (IGF-1R) inhibitors (AVE1642 human antibody and linsitinib) significantly potentiated the efficacy of trabectedin both <i>in vitro</i> and <i>in vivo</i>. This highly synergistic cytotoxic combination was attributed to the ability of trabectedin to increase the occupancy of EWS/FLI to IGF-1R promoters, leading to IGF-1R upregulation. In contrast, binding of EWS/FLI (type I and type II) to the <i>TGFβR2</i> and <i>CD99</i> genes was strongly suppressed following both trabectedin and doxorubicin treatment<sup><a href="#ref-38">38</a></sup>. Indeed, EWS/FLI has been shown to directly affect IGF-1R signaling through suppression of IGFBP-3 (insulin-like growth factor-binding protein-3), leading to constitutive activation of the IGF-1 pathway<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>.</p><p class="" id=d2834e994>Despite the nanomolar sensitivity of Ewing sarcoma cells <i>in vitro</i>, trabectedin did not demonstrate sufficient single-agent activity in the recent Children’s Oncology Group (COG) phase II trial of trabectedin in children with recurrent Ewing sarcoma<sup><a href="#ref-41">41</a></sup>. Of the 10 evaluable patients with Ewing sarcoma, one patient achieved stable disease (15 cycles), and progressive disease was reported for the remaining nine patients. Grohar <i>et al.</i> hypothesized that these disappointing clinical results may be attributed to a narrow therapeutic index that limited or transiently achieved the required serum levels necessary to sufficiently inhibit EWS/FLI activity<sup><a href="#ref-34">34</a></sup>. Patient maximum concentration (C<sub>max</sub>) plasma levels of 2.49 ± 2.25 ng/ml (1.5 mg/m<sup>2</sup> dose) were attained and this was significantly lower than the 5–10 nmol/L trabectedin concentration required to suppress EWS/FLI downstream target expression <i>in vitro</i><sup><a href="#ref-34">34</a>,<a href="#ref-41">41</a></sup>. In the initial phase I refractory solid tumor COG pharmacokinetic study of trabectedin, the only complete response documented was observed from a patient with Ewing sarcoma and was sustained for 10 months before recurrence 3 months after cessation of treatment<sup><a href="#ref-42">42</a></sup>. Unlike those in the phase II trial, patients in the phase I trial achieved C<sub>max</sub> plasma levels of 10.52 ± 5.00 ng/ml (1.3 mg/m<sup>2</sup> dose). Although trabectedin in combination with olaparib is currently being assessed in a phase 1b clinical trial for patients with unresectable advanced/metastatic sarcomas (NCT02398058) (<a href="#T1">Table 1</a>), camptothecins should also be considered to suppress the EWS/FLI-mediated tumorigenic gene signature.</p><p class="" id=d2834e1041>Recently, Hensel <i>et al.</i> demonstrated that EWS/FLI expression levels are significantly reduced in Ewing sarcoma cell lines following treatment with the BET (bromo and extraterminal) inhibitor JQ1<sup><a href="#ref-43">43</a></sup>. It is proposed that JQ1 binds competitively to acetyl-lysine recognition motifs, thereby displacing bromodomain fusion oncoproteins such as BRD4 from chromatin<sup><a href="#ref-44">44</a></sup>. In addition to caspase-dependent apoptosis, microarray analysis of JQ1-treated Ewing sarcoma cell lines demonstrated significant downregulation of EWS/FLI transcriptional targets, including <i>DKK2</i>, <i>EZH2</i>, <i>GPR64</i>, <i>STEAP1</i>, and <i>STK32B</i>. This reversal of EWS/FLI gene expression pattern was exclusively mirrored through siRNA-mediated knockdown of BRD3 and BRD4 but not BRD2, suggesting that BRD3 and BRD4 may be critical epigenetic regulators in Ewing sarcoma. Although complete Ewing sarcoma xenograft tumor response was not observed following single-agent JQ1 treatment, these early preclinical findings suggest that combination treatment with epigenetic inhibitors that block BET bromodomain activity and the associated EWS/FLI transcriptional program may represent a potential therapeutic platform for Ewing sarcoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e1074>Inhibitors of lysine-specific demethylase 1</h2><p class="" id=d2834e1077>Gene expression profiling and tissue microarray analysis of more than 500 sarcomas by Bennani-Baiti <i>et al.</i> revealed that the FAD monoamine oxidase LSD1 (lysine-specific demethylase 1, KDM1A) is highly overexpressed in Ewing sarcoma<sup><a href="#ref-45">45</a></sup>. Indeed, analysis of the Broad Institute Cell Line Encyclopedia<sup><a href="#ref-46">46</a></sup> indicates that Ewing sarcoma is the second highest LSD1-expressing malignancy out of a comprehensive panel of 36 cancer subtypes. Previous mechanistic studies conducted by our laboratory suggested that the transcriptional repressive function of EWS/FLI is mediated through interaction with the NuRD co-repressor complex in which LSD1 functions as a key component<sup><a href="#ref-27">27</a></sup>. As such, the high expression of LSD1 in Ewing sarcoma, coupled with the absence of mutations<sup><a href="#ref-47">47</a></sup> and its critical role in EWS/FLI transcriptional repression, provides a strong case for therapeutic intervention. Although the development of specific LSD1 inhibitors is still in its infancy, treatment of Ewing sarcoma cell lines with the specific and non-competitive reversible LSD1 inhibitor HCI-2509 (<a href="#f1">Figure 1</a>) comprehensively reversed the transcriptional signature driven by both EWS/FLI and EWS/ERG<sup><a href="#ref-27">27</a>,<a href="#ref-48">48</a></sup>. In addition, cells expressing EWS/FLI were approximately 10-fold more susceptible to the apoptotic cytotoxic effects of HCI-2509, underscoring the specificity of HCI-2509 for the treatment of Ewing sarcoma. Currently, three irreversible LSD1 inhibitory agents—tranylcypromine, GSK-2879552, and ORY-100—are undergoing clinical evaluation primarily in patients with acute myeloid leukemia<sup><a href="#ref-47">47</a></sup>, and clinical formulations of HCI-2509 are expected to enter phase I testing in 2017. Findings from these trials will guide the impetus for targeting LSD1-overexpressing cancers and have the potential to be a significant component in the armamentarium arsenal for the treatment of Ewing sarcoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e1117>Inhibitors of poly ADP ribose polymerase</h2><p class="" id=d2834e1120>The PARP superfamily of multi-functional enzymes comprises 18 members, and PARP-1 is the most abundant (&gt;85% of PARP activity)<sup><a href="#ref-49">49</a></sup>. The most well-established role of PARP-1 is the spatial and temporal organization of DNA single-strand break base excision repair with inhibition leading to stalled/collapsed replication forks and consequently catastrophic DNA double-strand breaks. Analysis of the Broad Institute Cell Line Encyclopedia<sup><a href="#ref-46">46</a></sup> indicates that Ewing sarcoma is the fifth highest PARP-1-expressing malignancy and that expression is significantly higher than that of other solid bone sarcomas such as osteosarcoma (<i>P</i> = 0.0400) and chondrosarcoma (<i>P</i> = 0.0176) (<a href="#f2">Figure 2a</a>). Oncomine tumor microarray analysis also indicates that PARP-1 is highly expressed in Ewing tumors<sup><a href="#ref-50">50</a>–<a href="#ref-53">53</a></sup> (<a href="#f2">Figure 2b</a>) but is not associated with overall or event-free survival, even though significantly higher expression was observed in relapsed patients (<i>P</i> = 0.0252)<sup><a href="#ref-51">51</a></sup> (<a href="#f2">Figure 2b, c</a>). In addition, mutations in PARP-1 and PARP-2 are seldom observed in Ewing sarcoma (<a href="#T2">Table 2</a>). Recent whole genome/exome sequencing studies of Ewing sarcoma tumors<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a>,<a href="#ref-54">54</a>–<a href="#ref-56">56</a></sup> identified PARP-1/2 mutations in only 1 out of 279 (0.36%) and 2 out of 279 (0.72%) patient tumor samples, respectively. This empirical evidence, coupled with two landmark studies that highlighted the exquisite hypersensitivity of Ewing sarcoma cell lines to PARP inhibitors<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>, provided the premise for targeted PARP intervention for the treatment of Ewing sarcoma.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9285/3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure2.gif"><img alt="3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9285/3f654bf4-8daf-4e7d-89da-88759fcc5d45_figure2.gif"></a><div class=caption><h3>Figure 2. PARP-1 is highly expressed in Ewing sarcoma tumors and cell lines.</h3><p id=d2834e1195>(<b>a</b>) Broad Institute PARP-1 expression across a panel of 1,036 cell lines. (<b>b</b>) PARP-1 expression (microarray) in Ewing sarcoma tumors and cell lines. (<b>c</b>) PARP-1 expression is not correlated with overall or event-free survival in Ewing sarcoma (n = 20). Survival data sourced from Ohali <i>et al.</i><sup><a href="#ref-51">51</a></sup> (2004). PARP-1, poly ADP ribose polymerase 1.</p></div></div><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Frequency of PARP-1 and PARP-2 mutations in Ewing sarcoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2834e1228 class=n-a></a><thead><a name=d2834e1230 class=n-a></a><tr><a name=d2834e1232 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e1234 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e1237 class=n-a></a>Sequencing platform</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e1240 class=n-a></a>Patient cohort</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e1243 class=n-a></a>PARP-1 mutations</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2834e1246 class=n-a></a>PARP-2 mutations</th></tr></thead><tbody><a name=d2834e1251 class=n-a></a><tr><a name=d2834e1253 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1255 class=n-a></a>Crompton <i>et al.</i><sup><a href="#ref-13">13</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1263 class=n-a></a>WES</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1266 class=n-a></a>n = 92</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1269 class=n-a></a>n = 1 (1.1%) (K203R)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1272 class=n-a></a>n = 2 (E222Q, H428H)</td></tr><tr><a name=d2834e1276 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1278 class=n-a></a>Tirode <i>et al.</i><sup><a href="#ref-56">56</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1286 class=n-a></a>WGS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1289 class=n-a></a>n = 112</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1292 class=n-a></a>n = 0 (0%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1295 class=n-a></a>n = 0 (0%)</td></tr><tr><a name=d2834e1299 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1301 class=n-a></a>Agelopoulos <i>et al.</i><sup><a href="#ref-54">54</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1309 class=n-a></a>WES</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1312 class=n-a></a>n = 50</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1315 class=n-a></a>n = 0 (0%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1318 class=n-a></a>n = 0 (0%)</td></tr><tr><a name=d2834e1322 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1324 class=n-a></a>Huether <i>et al.</i><sup><a href="#ref-55">55</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1332 class=n-a></a>WGS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1335 class=n-a></a>n = 19</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1338 class=n-a></a>n = 0 (0%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1341 class=n-a></a>n = 0 (0%)</td></tr><tr><a name=d2834e1345 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1347 class=n-a></a>Brohl <i>et al.</i><sup><a href="#ref-12">12</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1355 class=n-a></a>WGS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1358 class=n-a></a>n = 6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1361 class=n-a></a>n = 0 (0%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1364 class=n-a></a>n = 0 (0%)</td></tr><tr><a name=d2834e1369 class=n-a></a><td align=left colspan=3 rowspan=1 valign=top><a name=d2834e1371 class=n-a></a>Total</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1374 class=n-a></a>n = 1/279 (0.36%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2834e1377 class=n-a></a>n = 2/279 (0.72%)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN2 class=n-a></a><p id=d2834e1386> PARP, poly ADP ribose polymerase; WES, whole exome sequencing; WGS, whole genome sequencing.</p></div></div></div><p class="" id=d2834e1391>Comprehensive drug screening (130 compounds) across 639 human tumor cell lines by Garnett <i>et al.</i><sup><a href="#ref-57">57</a></sup> identified a highly significant association between the presence of the EWS/FLI rearrangement and olaparib (Lynparza) sensitivity (geometric mean IC<sub>50</sub> for EWS/FLI = 4.7 versus 64 μM for non-EWS/FLI lines). Indeed, sensitivity of Ewing sarcoma cell lines to both olaparib and the structurally distinct PARP inhibitor AG-014699 was comparable to that observed in BRCA-deficient cell lines and greater than that observed from other solid bone and soft tissue sarcomas. Mechanistic investigations by Brenner <i>et al.</i> validated that the marked sensitivity of Ewing sarcoma cell lines to olaparib could be attributed to a positive feedback loop in which the EWS/FLI fusion drives and maintains PARP-1 expression, which in turn further promotes transcriptional activation by EWS/FLI<sup><a href="#ref-58">58</a></sup>. Knockdown of EWS/FLI in Ewing sarcoma cells led to a significant reduction in both PARP-1 protein expression and promoter activity. Surprisingly, marked differences in single-agent cytotoxicity across several PARP inhibitors (talazoparib, niraparib, olaparib, and veliparib) has been documented, and talazoparib (BMN-673) and veliparib are the most and least active compounds in Ewing sarcoma, respectively<sup><a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>. In addition to catalytic inhibition, PARP inhibitors exert their cytotoxicity by tightly trapping PARP-1 and PARP-2 to DNA at sites of single-strand breaks, and <i>in vitro</i> Ewing sarcoma inhibitor sensitivity correlates with PARP trapping potential<sup><a href="#ref-60">60</a>,<a href="#ref-62">62</a></sup>. Whole exome sequencing of Ewing sarcoma cell lines revealed an absence of mutations in DNA repair genes, and as both ATM and ATR DDR signaling pathways remain functional in Ewing sarcoma, PARP inhibitor sensitivity is not underpinned by mutational defects in DNA repair by homologous recombination but perhaps through hypersensitivity to trapped PARP-1 DNA complexes<sup><a href="#ref-61">61</a></sup>.</p><p class="" id=d2834e1433>Despite the acute hypersensitivity of Ewing sarcoma cell lines to numerous PARP inhibitors <i>in vitro</i>, these results did not translate directly to single-agent xenograft responses <i>in vivo</i><sup><a href="#ref-58">58</a>,<a href="#ref-60">60</a>,<a href="#ref-63">63</a>–<a href="#ref-65">65</a></sup>. Olaparib monotherapy only led to a significant delay in Ewing sarcoma xenograft models. However, combined treatment with the DNA-alkylating agent temozolomide resulted in sustained complete responses without observable recurrence<sup><a href="#ref-58">58</a></sup>. Consistent with the minimal activity of single-agent olaparib in Ewing sarcoma xenografts, no objective responses (partial or complete) were observed from the first phase II study of olaparib (NCT01583543) in 12 patients with refractory Ewing sarcoma, median time to progression was 5.7 weeks<sup><a href="#ref-66">66</a></sup>, thus underscoring the requirement for combination therapies. To investigate the ability of PARP inhibitors to modulate the chemosensitivity of Ewing sarcoma, Engert <i>et al.</i> screened PARP synergistic drug interactions with Ewing sarcoma chemotherapeutic backbone cassettes<sup><a href="#ref-59">59</a></sup>. Indeed, the strongest synergism was observed in combination with temozolomide followed by SN38, with diminutive synergistic effects observed with actinomycin D and vincristine. Of note, triple therapy comprising olaparib, temozolomide, and SN38 significantly reduced the viability of Ewing sarcoma cells compared with single-agent or co-treatment with temozolomide or SN38 <i>in vitro</i>. Consistent with these findings, no significant difference was observed in overall survival in a phase III preclinical orthotropic mouse model of Ewing sarcoma treated with placebo or single-agent PARP inhibitors veliparib, olaparib, and talazoparib<sup><a href="#ref-60">60</a></sup>. However, combination of PARP inhibitors (olaparib or BMN-673) with temozolomide and irinotecan gave complete and durable responses in 71–88% of mice respectively.</p><p class="" id=d2834e1477>Inhibitors of PARP have emerged as a novel class of agents to treat Ewing sarcoma, and several clinical studies are underway (<a href="#T1">Table 1</a>). It is clear that single-agent PARP treatment is ineffective and will require strategic combinatorial strategies with temozolomide, topoisomerase I poisons, or radiotherapy to achieve maximal therapeutic effect. Results from these ongoing adult studies are eagerly awaited to help guide future trials for pediatric and adolescent patients with Ewing sarcoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2834e1487>Conclusions</h2><p class="" id=d2834e1490>Though Ewing sarcoma was first described 95 years ago, its treatment still relies on conventional multi-agent chemotherapeutic regiments in combination with surgery or radiotherapy or both. This current backbone is associated with considerable acute and long-term toxicities, and since further modification of the five-drug chemotherapeutic cassette seems unlikely to produce additional benefits, successful integration of novel targeted agents is urgently required in order to improve outcomes for patients with relapsed and metastatic disease. The first attempt of targeted therapy integration is currently being undertaken in a randomized phase II trial evaluating the addition of ganitumab (IGF-1R human monoclonal antibody) to multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide) for patients with newly diagnosed metastatic Ewing sarcoma (AEWS1221/NCT02306161). It is hoped that combining IGF-1R targeted agents with conventional therapy may lower the effective dosage of radiotherapy and chemotherapy in addition to minimizing side effects while maintaining efficacy.</p><p class="" id=d2834e1493>Metastatic disease at the time of presentation or at relapse remains the single most powerful predictor of outcome in Ewing sarcoma, and the mechanisms that drive metastasis remain largely unknown. Whether targeted agents that directly inhibit critical EWS/FLI protein-protein interactions or reverse the EWS/FLI transcriptional signature can successfully prevent or delay tumor progression remains as yet unanswered and will be the focus of the next generation of phase I/II trials, whose ultimate goal is to determine whether these novel therapies can significantly improve survival outcomes for patients with Ewing sarcoma.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d2834e1 class=n-a></a><h2 class=main-title id=d3063>Competing interests</h2><p class=metadata-entry><a name=d2834e107 class=n-a></a><p id=d2834e108> KIP declares that she has no competing interests. SLL is the Acting Chief Medical Officer for Salarius Pharmaceuticals, LLC, (Salt Lake City, UT).</p></p></div><div class=back-section><a name=d2834e1 class=n-a></a><h2 class=main-title id=d3065>Grant information</h2><p>SLL was supported by National Institutes of Health/National Cancer Institute grants R01 CA140394 and R01 CA183776, the Pediatric Cancer Foundation Sunshine Project, and the Alan B. Slifka Foundation. KIP acknowledges financial support from the University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship and the National Health and Medical Research Council CJ Martin Overseas Biomedical Fellowship.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d2834e1500 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d3291>References</h2><div class="section ref-list"><a name=d2834e1500 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d2834e1507 class=n-a></a>Gaspar N, Hawkins DS, Dirksen U, <i> et al.</i>: Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. <i>J Clin Oncol.</i> 2015; <b>33</b>(27): 3036–46. <a target=xrefwindow id=d2834e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/26304893">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1521 href="http://dx.doi.org/10.1200/JCO.2014.59.5256">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d2834e1530 class=n-a></a>Balamuth NJ, Womer RB: Ewing's sarcoma. <i>Lancet Oncol.</i> 2010; <b>11</b>(2): 184–92. <a target=xrefwindow id=d2834e1538 href="http://www.ncbi.nlm.nih.gov/pubmed/20152770">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1541 href="http://dx.doi.org/10.1016/S1470-2045(09)70286-4">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d2834e1550 class=n-a></a>Toomey EC, Schiffman JD, Lessnick SL: Recent advances in the molecular pathogenesis of Ewing's sarcoma. <i>Oncogene.</i> 2010; <b>29</b>(32): 4504–16. <a target=xrefwindow id=d2834e1558 href="http://www.ncbi.nlm.nih.gov/pubmed/20543858">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1561 href="http://dx.doi.org/10.1038/onc.2010.205">Publisher Full Text </a> | <a target=xrefwindow id=d2834e1564 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3555143">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d2834e1573 class=n-a></a>Delattre O, Zucman J, Plougastel B, <i> et al.</i>: Gene fusion with an <i>ETS</i> DNA-binding domain caused by chromosome translocation in human tumours. <i>Nature.</i> 1992; <b>359</b>(6391): 162–5. <a target=xrefwindow id=d2834e1587 href="http://www.ncbi.nlm.nih.gov/pubmed/1522903">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1591 href="http://dx.doi.org/10.1038/359162a0">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d2834e1600 class=n-a></a>Sorensen PH, Lessnick SL, Lopez-Terrada D, <i> et al.</i>: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. <i>Nat Genet.</i> 1994; <b>6</b>(2): 146–51. <a target=xrefwindow id=d2834e1611 href="http://www.ncbi.nlm.nih.gov/pubmed/8162068">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1614 href="http://dx.doi.org/10.1038/ng0294-146">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d2834e1624 class=n-a></a>Jeon IS, Davis JN, Braun BS, <i> et al.</i>: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. <i>Oncogene.</i> 1995; <b>10</b>(6): 1229–34. <a target=xrefwindow id=d2834e1635 href="http://www.ncbi.nlm.nih.gov/pubmed/7700648">PubMed Abstract </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d2834e1644 class=n-a></a>Kaneko Y, Yoshida K, Handa M, <i> et al.</i>: Fusion of an <i>ETS</i>-family gene, <i>EIAF</i>, to <i>EWS</i> by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. <i>Genes Chromosomes Cancer.</i> 1996; <b>15</b>(2): 115–21. <a target=xrefwindow id=d2834e1665 href="http://www.ncbi.nlm.nih.gov/pubmed/8834175">PubMed Abstract </a> | <a target="xrefwindow" id="d2834e1668" href="http://dx.doi.org/10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6&gt;3.0.CO;2-6">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d2834e1677 class=n-a></a>Urano F, Umezawa A, Hong W, <i> et al.</i>: A novel chimera gene between <i>EWS</i> and <i>E1A-F</i>, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. <i>Biochem Biophys Res Commun.</i> 1996; <b>219</b>(2): 608–12. <a target=xrefwindow id=d2834e1695 href="http://www.ncbi.nlm.nih.gov/pubmed/8605035">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1698 href="http://dx.doi.org/10.1006/bbrc.1996.0281">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d2834e1707 class=n-a></a>Peter M, Couturier J, Pacquement H, <i> et al.</i>: A new member of the ETS family fused to EWS in Ewing tumors. <i>Oncogene.</i> 1997; <b>14</b>(10): 1159–64. <a target=xrefwindow id=d2834e1718 href="http://www.ncbi.nlm.nih.gov/pubmed/9121764">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1721 href="http://dx.doi.org/10.1038/sj.onc.1200933">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d2834e1730 class=n-a></a>Turc-Carel C, Aurias A, Mugneret F, <i> et al.</i>: Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). <i>Cancer Genet Cytogenet.</i> 1988; <b>32</b>(2): 229–38. <a target=xrefwindow id=d2834e1741 href="http://www.ncbi.nlm.nih.gov/pubmed/3163261">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1744 href="http://dx.doi.org/10.1016/0165-4608(88)90285-3">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13382963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e1753 class=n-a></a>Patel M, Simon JM, Iglesia MD, <i> et al.</i>: Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. <i>Genome Res.</i> 2012; <b>22</b>(2): 259–70. <a target=xrefwindow id=d2834e1764 href="http://www.ncbi.nlm.nih.gov/pubmed/22086061">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1767 href="http://dx.doi.org/10.1101/gr.125666.111">Publisher Full Text </a> | <a target=xrefwindow id=d2834e1771 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3266033">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13382963">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718486848"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e1785 class=n-a></a>Brohl AS, Solomon DA, Chang W, <i> et al.</i>: The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent <i>STAG2</i> mutation. <i>PLoS Genet.</i> 2014; <b>10</b>(7): e1004475. <a target=xrefwindow id=d2834e1799 href="http://www.ncbi.nlm.nih.gov/pubmed/25010205">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1803 href="http://dx.doi.org/10.1371/journal.pgen.1004475">Publisher Full Text </a> | <a target=xrefwindow id=d2834e1806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4091782">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718486848">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718632867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e1819 class=n-a></a>Crompton BD, Stewart C, Taylor-Weiner A, <i> et al.</i>: The genomic landscape of pediatric Ewing sarcoma. <i>Cancer Discov.</i> 2014; <b>4</b>(11): 1326–41. <a target=xrefwindow id=d2834e1830 href="http://www.ncbi.nlm.nih.gov/pubmed/25186949">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1833 href="http://dx.doi.org/10.1158/2159-8290.CD-13-1037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718632867">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d2834e1846 class=n-a></a>Aurias A, Rimbaut C, Buffe D, <i> et al.</i>: [Translocation of chromosome 22 in Ewing's sarcoma]. <i>C R Seances Acad Sci III.</i> 1983; <b>296</b>(23): 1105–7. <a target=xrefwindow id=d2834e1857 href="http://www.ncbi.nlm.nih.gov/pubmed/6416623">PubMed Abstract </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d2834e1866 class=n-a></a>Chansky HA, Barahmand-Pour F, Mei Q, <i> et al.</i>: Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells <i>in vitro</i>. <i>J Orthop Res.</i> 2004; <b>22</b>(4): 910–7. <a target=xrefwindow id=d2834e1880 href="http://www.ncbi.nlm.nih.gov/pubmed/15183454">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1884 href="http://dx.doi.org/10.1016/j.orthres.2003.12.008">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d2834e1893 class=n-a></a>Ouchida M, Ohno T, Fujimura Y, <i> et al.</i>: Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. <i>Oncogene.</i> 1995; <b>11</b>(6): 1049–54. <a target=xrefwindow id=d2834e1904 href="http://www.ncbi.nlm.nih.gov/pubmed/7566963">PubMed Abstract </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d2834e1913 class=n-a></a>Tanaka K, Iwakuma T, Harimaya K, <i> et al.</i>: EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. <i>J Clin Invest.</i> 1997; <b>99</b>(2): 239–47. <a target=xrefwindow id=d2834e1924 href="http://www.ncbi.nlm.nih.gov/pubmed/9005992">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1927 href="http://dx.doi.org/10.1172/JCI119152">Publisher Full Text </a> | <a target=xrefwindow id=d2834e1931 href="http://www.ncbi.nlm.nih.gov/pmc/articles/507791">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d2834e1941 class=n-a></a>Toretsky JA, Connell Y, Neckers L, <i> et al.</i>: Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. <i>J Neurooncol.</i> 1997; <b>31</b>(1–2): 9–16. <a target=xrefwindow id=d2834e1952 href="http://www.ncbi.nlm.nih.gov/pubmed/9049825">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1955 href="http://dx.doi.org/10.1023/A:1005716926800">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d2834e1964 class=n-a></a>Smith R, Owen LA, Trem DJ, <i> et al.</i>: Expression profiling of EWS/FLI identifies <i>NKX2.2</i> as a critical target gene in Ewing's sarcoma. <i>Cancer Cell.</i> 2006; <b>9</b>(5): 405–16. <a target=xrefwindow id=d2834e1978 href="http://www.ncbi.nlm.nih.gov/pubmed/16697960">PubMed Abstract </a> | <a target=xrefwindow id=d2834e1982 href="http://dx.doi.org/10.1016/j.ccr.2006.04.004">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d2834e1991 class=n-a></a>Ng KP, Potikyan G, Savene RO, <i> et al.</i>: Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. <i>Proc Natl Acad Sci U S A.</i> 2007; <b>104</b>(2): 479–84. <a target=xrefwindow id=d2834e2002 href="http://www.ncbi.nlm.nih.gov/pubmed/17202261">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2005 href="http://dx.doi.org/10.1073/pnas.0607007104">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1766410">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d2834e2018 class=n-a></a>Uren A, Tcherkasskaya O, Toretsky JA: Recombinant EWS-FLI1 oncoprotein activates transcription. <i>Biochemistry.</i> 2004; <b>43</b>(42): 13579–89. <a target=xrefwindow id=d2834e2026 href="http://www.ncbi.nlm.nih.gov/pubmed/15491164">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2029 href="http://dx.doi.org/10.1021/bi048776q">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1161799"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2038 class=n-a></a>Erkizan HV, Kong Y, Merchant M, <i> et al.</i>: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. <i>Nat Med.</i> 2009; <b>15</b>(7): 750–6. <a target=xrefwindow id=d2834e2049 href="http://www.ncbi.nlm.nih.gov/pubmed/19584866">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2052 href="http://dx.doi.org/10.1038/nm.1983">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2777681">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1161799">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/721226197"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2069 class=n-a></a>Barber-Rotenberg JS, Selvanathan SP, Kong Y, <i> et al.</i>: Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. <i>Oncotarget.</i> 2012; <b>3</b>(2): 172–82. <a target=xrefwindow id=d2834e2080 href="http://www.ncbi.nlm.nih.gov/pubmed/22383402">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2083 href="http://dx.doi.org/10.18632/oncotarget.454">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2087 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3326647">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/721226197">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726637189"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2101 class=n-a></a>Hong SH, Youbi SE, Hong SP, <i> et al.</i>: Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. <i>Oncotarget.</i> 2014; <b>5</b>(2): 338–50. <a target=xrefwindow id=d2834e2112 href="http://www.ncbi.nlm.nih.gov/pubmed/24481407">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2115 href="http://dx.doi.org/10.18632/oncotarget.1495">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3964211">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726637189">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725375969"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2132 class=n-a></a>Selvanathan SP, Graham GT, Erkizan HV, <i> et al.</i>: Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. <i>Proc Natl Acad Sci U S A.</i> 2015; <b>112</b>(11): E1307–16. <a target=xrefwindow id=d2834e2143 href="http://www.ncbi.nlm.nih.gov/pubmed/25737553">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2146 href="http://dx.doi.org/10.1073/pnas.1500536112">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4371969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725375969">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725490664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2163 class=n-a></a>Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, <i> et al.</i>: An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(7): 1591–604. <a target=xrefwindow id=d2834e2174 href="http://www.ncbi.nlm.nih.gov/pubmed/25964201">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2177 href="http://dx.doi.org/10.1158/1535-7163.MCT-14-0334">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725490664">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d2834e2190 class=n-a></a>Sankar S, Bell R, Stephens B, <i> et al.</i>: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. <i>Oncogene.</i> 2013; <b>32</b>(42): 5089–100. <a target=xrefwindow id=d2834e2201 href="http://www.ncbi.nlm.nih.gov/pubmed/23178492">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2204 href="http://dx.doi.org/10.1038/onc.2012.525">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2208 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3899696">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d2834e2217 class=n-a></a>Grosso F, Jones RL, Demetri GD, <i> et al.</i>: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncol.</i> 2007; <b>8</b>(7): 595–602. <a target=xrefwindow id=d2834e2228 href="http://www.ncbi.nlm.nih.gov/pubmed/17586092">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2231 href="http://dx.doi.org/10.1016/S1470-2045(07)70175-4">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d2834e2240 class=n-a></a>Grosso F, Sanfilippo R, Virdis E, <i> et al.</i>: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. <i>Ann Oncol.</i> 2009; <b>20</b>(8): 1439–44. <a target=xrefwindow id=d2834e2251 href="http://www.ncbi.nlm.nih.gov/pubmed/19465423">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2254 href="http://dx.doi.org/10.1093/annonc/mdp004">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d2834e2264 class=n-a></a>Forni C, Minuzzo M, Virdis E, <i> et al.</i>: Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. <i>Mol Cancer Ther.</i> 2009; <b>8</b>(2): 449–57. <a target=xrefwindow id=d2834e2275 href="http://www.ncbi.nlm.nih.gov/pubmed/19190116">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2278 href="http://dx.doi.org/10.1158/1535-7163.MCT-08-0848">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d2834e2287 class=n-a></a>Cuevas C, Francesch A: Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. <i>Nat Prod Rep.</i> 2009; <b>26</b>(3): 322–37. <a target=xrefwindow id=d2834e2295 href="http://www.ncbi.nlm.nih.gov/pubmed/19240944">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2298 href="http://dx.doi.org/10.1039/b808331m">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d2834e2307 class=n-a></a>D'Incalci M, Galmarini CM: A review of trabectedin (ET-743): a unique mechanism of action. <i>Mol Cancer Ther.</i> 2010; <b>9</b>(8): 2157–63. <a target=xrefwindow id=d2834e2315 href="http://www.ncbi.nlm.nih.gov/pubmed/20647340">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2318 href="http://dx.doi.org/10.1158/1535-7163.MCT-10-0263">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/10540956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a>F1000 Recommendation<a name=d2834e2327 class=n-a></a>Grohar PJ, Griffin LB, Yeung C, <i> et al.</i>: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. <i>Neoplasia.</i> 2011; <b>13</b>(2): 145–53. <a target=xrefwindow id=d2834e2338 href="http://www.ncbi.nlm.nih.gov/pubmed/21403840">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2341 href="http://dx.doi.org/10.1593/neo.101202">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2345 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3033593">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/10540956">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718188685"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2358 class=n-a></a>Grohar PJ, Segars LE, Yeung C, <i> et al.</i>: Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. <i>Clin Cancer Res.</i> 2014; <b>20</b>(5): 1190–203. <a target=xrefwindow id=d2834e2369 href="http://www.ncbi.nlm.nih.gov/pubmed/24277455">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2372 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0901">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718188685">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d2834e2385 class=n-a></a>Boro A, Prêtre K, Rechfeld F, <i> et al.</i>: Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. <i>Int J Cancer.</i> 2012; <b>131</b>(9): 2153–64. <a target=xrefwindow id=d2834e2396 href="http://www.ncbi.nlm.nih.gov/pubmed/22323082">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2399 href="http://dx.doi.org/10.1002/ijc.27472">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d2834e2409 class=n-a></a>Pichierri P, Franchitto A, Mosesso P, <i> et al.</i>: Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle. <i>Mutat Res.</i> 2000; <b>459</b>(2): 123–33. <a target=xrefwindow id=d2834e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/10725663">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2423 href="http://dx.doi.org/10.1016/S0921-8777(99)00065-8">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d2834e2432 class=n-a></a>Poot M, Gollahon KA, Rabinovitch PS: Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. <i>Hum Genet.</i> 1999; <b>104</b>(1): 10–4. <a target=xrefwindow id=d2834e2440 href="http://www.ncbi.nlm.nih.gov/pubmed/10071186">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2443 href="http://dx.doi.org/10.1007/s004390050903">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725322238"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2452 class=n-a></a>Amaral AT, Garofalo C, Frapolli R, <i> et al.</i>: Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. <i>Clin Cancer Res.</i> 2015; <b>21</b>(6): 1373–82. <a target=xrefwindow id=d2834e2463 href="http://www.ncbi.nlm.nih.gov/pubmed/25609059">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2466 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-1688">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725322238">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d2834e2479 class=n-a></a>Prieur A, Tirode F, Cohen P, <i> et al.</i>: EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. <i>Mol Cell Biol.</i> 2004; <b>24</b>(16): 7275–83. <a target=xrefwindow id=d2834e2490 href="http://www.ncbi.nlm.nih.gov/pubmed/15282325">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2493 href="http://dx.doi.org/10.1128/MCB.24.16.7275-7283.2004">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/479730">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d2834e2506 class=n-a></a>Olmos D, Martins AS, Jones RL, <i> et al.</i>: Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. <i>Sarcoma.</i> 2011; <b>2011</b>: 402508. <a target=xrefwindow id=d2834e2517 href="http://www.ncbi.nlm.nih.gov/pubmed/21647361">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2520 href="http://dx.doi.org/10.1155/2011/402508">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2524 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3103989">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/722539543"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2533 class=n-a></a>Baruchel S, Pappo A, Krailo M, <i> et al.</i>: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. <i>Eur J Cancer.</i> 2012; <b>48</b>(4): 579–85. <a target=xrefwindow id=d2834e2544 href="http://www.ncbi.nlm.nih.gov/pubmed/22088484">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2547 href="http://dx.doi.org/10.1016/j.ejca.2011.09.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/722539543">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d2834e2561 class=n-a></a>Lau L, Supko JG, Blaney S, <i> et al.</i>: A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. <i>Clin Cancer Res.</i> 2005; <b>11</b>(2 Pt 1): 672–7. <a target=xrefwindow id=d2834e2572 href="http://www.ncbi.nlm.nih.gov/pubmed/15701855">PubMed Abstract </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725975932"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2581 class=n-a></a>Hensel T, Giorgi C, Schmidt O, <i> et al.</i>: Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. <i>Oncotarget.</i> 2016; <b>7</b>(2): 1451–63. <a target=xrefwindow id=d2834e2592 href="http://www.ncbi.nlm.nih.gov/pubmed/26623725">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2595 href="http://dx.doi.org/10.18632/oncotarget.6385">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2599 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4811472">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725975932">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/5472966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2612 class=n-a></a>Filippakopoulos P, Qi J, Picaud S, <i> et al.</i>: Selective inhibition of BET bromodomains. <i>Nature.</i> 2010; <b>468</b>(7327): 1067–73. <a target=xrefwindow id=d2834e2623 href="http://www.ncbi.nlm.nih.gov/pubmed/20871596">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2626 href="http://dx.doi.org/10.1038/nature09504">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2630 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3010259">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/5472966">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d2834e2643 class=n-a></a>Bennani-Baiti IM, Machado I, Llombart-Bosch A, <i> et al.</i>: Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. <i>Hum Pathol.</i> 2012; <b>43</b>(8): 1300–7. <a target=xrefwindow id=d2834e2654 href="http://www.ncbi.nlm.nih.gov/pubmed/22245111">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2657 href="http://dx.doi.org/10.1016/j.humpath.2011.10.010">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14264142"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2666 class=n-a></a>Barretina J, Caponigro G, Stransky N, <i> et al.</i>: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. <i>Nature.</i> 2012; <b>483</b>(7391): 603–7. <a target=xrefwindow id=d2834e2677 href="http://www.ncbi.nlm.nih.gov/pubmed/22460905">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2680 href="http://dx.doi.org/10.1038/nature11003">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3320027">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14264142">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d2834e2697 class=n-a></a>Theisen ER, Pishas KI, Saund RS, <i> et al.</i>: Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition <i>via</i> LSD1 targeting. <i>Oncotarget.</i> 2016; <b>7</b>(14): 17616–30. <a target=xrefwindow id=d2834e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/26848860">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2715 href="http://dx.doi.org/10.18632/oncotarget.7124">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2718 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4951237">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d2834e2728 class=n-a></a>Sankar S, Theisen ER, Bearss J, <i> et al.</i>: Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. <i>Clin Cancer Res.</i> 2014; <b>20</b>(17): 4584–97. <a target=xrefwindow id=d2834e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/24963049">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2742 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-0072">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2746 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4155010">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d2834e2755 class=n-a></a>Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. <i>Bioessays.</i> 2004; <b>26</b>(8): 882–93. <a target=xrefwindow id=d2834e2763 href="http://www.ncbi.nlm.nih.gov/pubmed/15273990">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2766 href="http://dx.doi.org/10.1002/bies.20085">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d2834e2775 class=n-a></a>Ferreira BI, Alonso J, Carrillo J, <i> et al.</i>: Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. <i>Oncogene.</i> 2008; <b>27</b>(14): 2084–90. <a target=xrefwindow id=d2834e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/17952124">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2789 href="http://dx.doi.org/10.1038/sj.onc.1210845">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d2834e2798 class=n-a></a>Ohali A, Avigad S, Zaizov R, <i> et al.</i>: Prediction of high risk Ewing's sarcoma by gene expression profiling. <i>Oncogene.</i> 2004; <b>23</b>(55): 8997–9006. <a target=xrefwindow id=d2834e2809 href="http://www.ncbi.nlm.nih.gov/pubmed/15467746">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2812 href="http://dx.doi.org/10.1038/sj.onc.1208060">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14006958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2821 class=n-a></a>Postel-Vinay S, Véron AS, Tirode F, <i> et al.</i>: Common variants near <i>TARDBP</i> and <i>EGR2</i> are associated with susceptibility to Ewing sarcoma. <i>Nat Genet.</i> 2012; <b>44</b>(3): 323–7. <a target=xrefwindow id=d2834e2839 href="http://www.ncbi.nlm.nih.gov/pubmed/22327514">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2842 href="http://dx.doi.org/10.1038/ng.1085">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14006958">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1108606"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2855 class=n-a></a>Schaefer KL, Eisenacher M, Braun Y, <i> et al.</i>: Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. <i>Eur J Cancer.</i> 2008; <b>44</b>(5): 699–709. <a target=xrefwindow id=d2834e2866 href="http://www.ncbi.nlm.nih.gov/pubmed/18294840">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2869 href="http://dx.doi.org/10.1016/j.ejca.2008.01.020">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1108606">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725645964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2883 class=n-a></a>Agelopoulos K, Richter GH, Schmidt E, <i> et al.</i>: Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clin Cancer Res.</i> 2015; <b>21</b>(21): 4935–46. <a target=xrefwindow id=d2834e2894 href="http://www.ncbi.nlm.nih.gov/pubmed/26179511">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2897 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2744">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725645964">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718342878"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2910 class=n-a></a>Huether R, Dong L, Chen X, <i> et al.</i>: The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. <i>Nat Commun.</i> 2014; <b>5</b>: 3630. <a target=xrefwindow id=d2834e2921 href="http://www.ncbi.nlm.nih.gov/pubmed/24710217">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2924 href="http://dx.doi.org/ 10.1038/ncomms4630">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2928 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4119022">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718342878">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718878626"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2941 class=n-a></a>Tirode F, Surdez D, Ma X, <i> et al.</i>: Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of <i>STAG2</i> and <i>TP53</i> mutations. <i>Cancer Discov.</i> 2014; <b>4</b>(11): 1342–53. <a target=xrefwindow id=d2834e2959 href="http://www.ncbi.nlm.nih.gov/pubmed/25223734">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2962 href="http://dx.doi.org/10.1158/2159-8290.CD-14-0622">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4264969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718878626">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14267128"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e2978 class=n-a></a>Garnett MJ, Edelman EJ, Heidorn SJ, <i> et al.</i>: Systematic identification of genomic markers of drug sensitivity in cancer cells. <i>Nature.</i> 2012; <b>483</b>(7391): 570–5. <a target=xrefwindow id=d2834e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/22460902">PubMed Abstract </a> | <a target=xrefwindow id=d2834e2992 href="http://dx.doi.org/10.1038/nature11005">Publisher Full Text </a> | <a target=xrefwindow id=d2834e2996 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3349233">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14267128">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/719411014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3009 class=n-a></a>Brenner JC, Feng FY, Han S, <i> et al.</i>: PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. <i>Cancer Res.</i> 2012; <b>72</b>(7): 1608–13. <a target=xrefwindow id=d2834e3020 href="http://www.ncbi.nlm.nih.gov/pubmed/22287547">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3023 href="http://dx.doi.org/10.1158/0008-5472.CAN-11-3648">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3027 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3319786">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/719411014">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725836302"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3040 class=n-a></a>Engert F, Schneider C, Weibeta LM, <i> et al.</i>: PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. <i>Mol Cancer Ther.</i> 2015; <b>14</b>(12): 2818–30. <a target=xrefwindow id=d2834e3051 href="http://www.ncbi.nlm.nih.gov/pubmed/26438158">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3054 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0587">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725836302">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726637195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3068 class=n-a></a>Stewart E, Goshorn R, Bradley C, <i> et al.</i>: Targeting the DNA repair pathway in Ewing sarcoma. <i>Cell Rep.</i> 2014; <b>9</b>(3): 829–41. <a target=xrefwindow id=d2834e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/25437539">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3082 href="http://dx.doi.org/10.1016/j.celrep.2014.09.028">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3086 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4386669">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726637195">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725882679"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3099 class=n-a></a>Gill SJ, Travers J, Pshenichnaya I, <i> et al.</i>: Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. <i>PLoS One.</i> 2015; <b>10</b>(10): e0140988. <a target=xrefwindow id=d2834e3110 href="http://www.ncbi.nlm.nih.gov/pubmed/26505995">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3113 href="http://dx.doi.org/10.1371/journal.pone.0140988">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3117 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4624427">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725882679">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d2834e3130 class=n-a></a>Murai J, Huang SY, Das BB, <i> et al.</i>: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. <i>Cancer Res.</i> 2012; <b>72</b>(21): 5588–99. <a target=xrefwindow id=d2834e3141 href="http://www.ncbi.nlm.nih.gov/pubmed/23118055">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3144 href="http://dx.doi.org/10.1158/0008-5472.CAN-12-2753">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3528345">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725276920"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3157 class=n-a></a>Smith MA, Reynolds CP, Kang MH, <i> et al.</i>: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. <i>Clin Cancer Res.</i> 2015; <b>21</b>(4): 819–32. <a target=xrefwindow id=d2834e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/25500058">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3171 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2572">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4587665">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725276920">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718110185"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3188 class=n-a></a>Norris RE, Adamson PC, Nguyen VT, <i> et al.</i>: Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(1): 145–50. <a target=xrefwindow id=d2834e3199 href="http://www.ncbi.nlm.nih.gov/pubmed/24038812">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3202 href="http://dx.doi.org/10.1002/pbc.24697">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3849815">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718110185">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718892387"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3219 class=n-a></a>Smith MA, Hampton OA, Reynolds CP, <i> et al.</i>: Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: <i>PALB2</i> mutation predicts exceptional <i>in vivo</i> response to BMN 673. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(1): 91–8. <a target=xrefwindow id=d2834e3237 href="http://www.ncbi.nlm.nih.gov/pubmed/25263539">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3240 href="http://dx.doi.org/10.1002/pbc.25201">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3243 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4456187">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718892387">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725227692"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2834e3257 class=n-a></a>Choy E, Butrynski JE, Harmon DC, <i> et al.</i>: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. <i>BMC Cancer.</i> 2014; <b>14</b>: 813. <a target=xrefwindow id=d2834e3268 href="http://www.ncbi.nlm.nih.gov/pubmed/25374341">PubMed Abstract </a> | <a target=xrefwindow id=d2834e3271 href="http://dx.doi.org/10.1186/1471-2407-14-813">Publisher Full Text </a> | <a target=xrefwindow id=d2834e3275 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4230717">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725227692">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2077.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2077.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Cancer Therapeutics Laboratory, Center for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia<br/> <sup>2</sup> Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA<br/> <sup>3</sup> Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Ohio State University, Columbus, OH, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2077/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Aug 2016, 5:2077 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.8631.1">https://doi.org/10.12688/f1000research.8631.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Pishas KI and Lessnick SL. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9285 data-id=8631 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8631.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2077/v1/pdf?article_uuid=afc4d3b2-6c63-4924-9114-0aad794821f5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.8631.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Pishas KI and Lessnick SL. Recent advances in targeted therapy for Ewing sarcoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2077 (<a href="https://doi.org/10.12688/f1000research.8631.1" target=_blank>https://doi.org/10.12688/f1000research.8631.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=8631 id=mobile-track-article-signin-8631 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8631?target=/articles/5-2077.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9285 /> <input name=articleId type=hidden value=8631 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jason Yustein</strong>, Department of Pediatrics, Hematology-Oncology, Texas Children's Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Julia Glade Bender</strong>, Department of Pediatrics, Columbia University Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2077.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2077.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16718-15889></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16717-15890></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2077/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Aug 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jason Yustein</strong>, Department of Pediatrics, Hematology-Oncology, Texas Children's Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Julia Glade Bender</strong>, Department of Pediatrics, Columbia University Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2077.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2077/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in targeted therapy for Ewing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2077/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2077/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2077/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Pishas KI and Lessnick SL');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2077/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2077",
            templates : {
                twitter : "Recent advances in targeted therapy for Ewing sarcoma. Pishas KI and Lessnick SL, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2077/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in targeted therapy for Ewing sarcoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in targeted therapy for Ewing sarcoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/8631/9285")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9285");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15889": 0,
                           "15890": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "0c1f29be-16bd-439d-8c69-83302a3709de";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2077.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2077.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2077.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2077.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2077.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>